Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Dense Deposit Disease: Eculizumab

Department of Health written question – answered on 7th November 2016.

Alert me about debates like this

Photo of Andrea Jenkyns Andrea Jenkyns Conservative, Morley and Outwood

To ask the Secretary of State for Health, what information he holds on the use of eculizumab to treat a patient with dense deposit disease at Evelina Children's Hospital.

Photo of Andrea Jenkyns Andrea Jenkyns Conservative, Morley and Outwood

To ask the Secretary of State for Health, what recent assessment he has made of the case of Abi Longfellow and her access to eculizumab for the treatment of dense deposit disease.

Photo of David Mowat David Mowat The Parliamentary Under-Secretary of State for Health

No information is held centrally and no such assessment has been made by this Department.

Eculizumab is not a licensed treatment for Dense Deposit Disease and well-constructed clinical trials on effectiveness are yet to be carried out. A new policy proposition for its use in treating the disease before a patient has had a kidney transplant will be considered during 2016-17.

There is a published policy on use of this drug for the prevention of recurrence after a patient has had a transplant. A policy on the treatment of C3 glomerulopathy that occurs after a kidney transplant will be considered by the Clinical Priorities Advisory Group (CPAG) at its next meeting. CPAG reviews both patient benefits and cost considerations when making recommendations.

Does this answer the above question?

Yes0 people think so

No2 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.